Diagnosis and Management of Microcytic Anemia

Introduction to Microcytic Anemia

• A significantly low MCV of 7.5 fL requires immediate evaluation for iron deficiency anemia or thalassemia, with iron supplementation as first-line therapy while investigating the underlying cause, according to the American Society of Hematology 1

Causes of Microcytic Anemia

• Iron deficiency anemia is the most common cause of microcytic anemia, followed by thalassemia, especially beta thalassemia major, sideroblastic anemia, anemia of chronic disease with iron deficiency, and rare genetic disorders of iron metabolism or heme synthesis, as stated by the National Institute of Diabetes and Digestive and Kidney Diseases 1
• Thalassemia is characterized by a normal or elevated red blood cell count despite anemia, whereas iron deficiency is associated with a low or normal red blood cell count 2

Diagnostic Evaluation

• A complete blood count with RDW, reticulocyte count, iron studies, including serum ferritin, transferrin saturation, serum iron, and total iron binding capacity, and C-reactive protein to assess inflammation, should be performed to diagnose microcytic anemia, as recommended by the American College of Gastroenterology 3
• Initial assessment should include a complete blood count with MCV, RDW, reticulocyte count, serum ferritin, transferrin saturation, and C-reactive protein (to assess inflammation) 4, 2
• If MCV is low (<80 fL), checking RDW can help differentiate between thalassemia and iron deficiency anemia: RDW ≤14.0% and normal/elevated RBC count suggests thalassemia trait, while RDW >14.0% suggests iron deficiency anemia 4
• The combination of red blood cell distribution width (RDW) and mean corpuscular volume (MCV) can differentiate thalassemia from iron deficiency anemia, with a low MCV and normal RDW (≤14.0%) indicating thalassemia minor, and a low MCV and elevated RDW (>14.0%) suggesting iron deficiency anemia 4, 2
• Serum ferritin levels are normal or elevated in thalassemia, but low (<30 μg/L without inflammation, <100 μg/L with inflammation) in iron deficiency 2
• Transferrin saturation is normal in thalassemia, but low in iron deficiency 2
• Erythrocyte protoporphyrin is normal in thalassemia, but elevated (>30 μg/dL of whole blood or >70 μg/dL of red blood cells) in iron deficiency 4

Distinguishing Between Dehydration, True Anemia, and Dilutional Anemia

5

• The American Academy of Family Physicians recommends assessing hydration status before interpreting CBC results, and repeating CBC after rehydration if dehydration is suspected, to obtain accurate baseline values 5
• The American College of Physicians recommends always assessing and documenting hydration status when interpreting CBC results 5
• The European Society of Clinical Microbiology and Infectious Diseases suggests repeating CBC after adequate rehydration to obtain accurate baseline values in dehydrated patients 5

Distinguishing Between Dilutional Anemia and True Iron Deficiency Anemia

6

• Guideline societies recommend avoiding unnecessary transfusions in stable patients with dilutional anemia if oxygen delivery parameters are adequate, with a general threshold of Hb <70 g/L for transfusion, and Hb <80 g/L for cardiac patients 6, 7
• The Centers for Disease Control and Prevention recommends monitoring for resolution of dilutional anemia, with hemoglobin concentration typically normalizing as excess fluid is eliminated 6

Treatment of Iron Deficiency Anemia

• Oral iron therapy with ferrous sulfate 200 mg three times daily should be started immediately, with alternatives such as ferrous gluconate or ferrous fumarate if sulfate is not tolerated, and ascorbic acid (vitamin C) added to enhance absorption if response is poor, as recommended by the World Health Organization 3
• Iron therapy should continue for three months after hemoglobin normalization to replenish stores, as stated by the American Gastroenterological Association 3
• A therapeutic trial of iron can confirm the diagnosis of iron deficiency anemia 4

Treatment of Thalassemia

• For severe thalassemia, hematopoietic stem cell transplantation should be considered as the only curative option, with symptomatic treatment with erythrocyte transfusions and chelation therapy, and monitoring for iron overload, as recommended by the European Hematology Association 1
• DNA analysis is essential for confirming thalassemia, particularly in prenatal diagnosis and family screening, as recommended by the American College of Obstetricians and Gynecologists 8
• Family screening is crucial, especially in high-risk populations, including Mediterranean, Middle Eastern, African, and Southeast Asian populations, with specific mutations being more common in certain ethnic groups 8
• The Centers for Disease Control and Prevention suggests that thalassemia trait should be considered in patients of Mediterranean, African, Middle Eastern, or Southeast Asian ancestry when microcytic anemia is unresponsive to iron therapy 4

Monitoring and Follow-up

• Hemoglobin should be expected to rise by 2 g/dL after 3-4 weeks of iron therapy, and if no response, compliance should be reassessed, and alternative diagnoses considered, as stated by the American Society of Clinical Oncology 3
• Follow-up monitoring should include checking hemoglobin and red cell indices every three months for one year, then annually for another year, with additional iron if hemoglobin or MCV falls below normal, as recommended by the National Comprehensive Cancer Network 3
• Coexisting conditions, such as microcytosis and macrocytosis, may neutralize each other, resulting in a normal MCV despite underlying iron deficiency 2
• Inflammation can elevate ferritin levels, potentially masking iron deficiency; in the presence of inflammation, ferritin up to 100 μg/L may still be consistent with iron deficiency 2
• Anemia can present with mild symptoms, particularly in patients of Mediterranean, African, Middle Eastern, or Southeast Asian ancestry, where thalassemia trait should be considered when microcytic anemia is unresponsive to iron therapy 4
• Dehydration can cause falsely normal or elevated hemoglobin and hematocrit values on a complete blood count (CBC), potentially masking true anemia or making it appear less severe than it actually is 5